89bio announces new positive long-term data from the enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash)

—data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests (nits) of liver injury/inflammation and fibrosis in nash patients with fibrosis stage f2-f3—

ETNB Ratings Summary

ETNB Quant Ranking